SPOTLIGHT -
Slideshow
Author(s):
There are a few things that we all agree on, as reflected in a recent consensus statement.
New 48-Week Remission Data on Ingrezza for the Treatment of Tardive Dyskinesia
Not All That Writhes Is Tardive Dyskinesia
Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia
Psychopharmacology Innovations
Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia
Why Clinicians Should Be Excited About Austedo XR